Results 101 to 110 of about 182,500 (270)

Pembrolizumab-induced duodenitis mimicking celiac disease

open access: yes
Pembrolizumab is a programmed cell death-1 (PD-1) inhibitor frequently used as primary immunotherapy in many cancers, including melanoma, lung, renal cell, cervical, urothelial, and gastric cancers. Given its immune-checkpoint inhibition and upregulation
Ehrenpreis, Eli D   +4 more
core   +1 more source

Pembrolizumab-related renal toxicities: diagnosis first, treatment later

open access: yes, 2019
Checkpoint inhibitors are increasingly used to treat different types of malignancy and have been associated with renal toxicities. In this issue, Izzedine et al. report on the incidence of pembrolizumab-associated renal toxicity in a French single-centre
Sprangers, Ben
core   +1 more source

Deterministic sensitivity analysis for the PD-L1-high model—pembrolizumab combination versus chemotherapy.

open access: yes, 2020
HR, hazard ratio; NSCLC, non-small cell lung cancer; ToT, time on treatment; OS, overall survival * Pembrolizumab combination therapy did not weakly dominate pembrolizumab monotherapy, therefore, the efficient frontier changed order and pembrolizumab ...
Juan Wisnivesky (8374794)   +6 more
core   +1 more source

Operationalization of the African Medicines Agency: Retrospective evaluation of the continental centralized pilot procedure timelines to recommendation and national registrations

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Regulatory inconsistency across Africa causes duplicative assessments, prolonged approvals, and delayed medical access. To inform the African Medicines Agency (AMA), the African Medicines Regulatory Harmonisation (AMRH) piloted Africa's first continental scientific evaluation of human medicinal products.
Alex Juma Ismail   +4 more
wiley   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

open access: yesBMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen   +9 more
wiley   +1 more source

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian   +12 more
wiley   +1 more source

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

open access: yes, 2017
Ashwin Somasundaram, Timothy F Burns Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA Abstract: Lung cancer is the leading killer of both men and women in the US, and the 5-year ...
Somasundaram A, Burns TF
core  

Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear.
Jyun‐Heng Lai   +12 more
wiley   +1 more source

OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer [PDF]

open access: yes
Patients with early-stage triple-negative breast cancer (TNBC) with residual invasive disease after neoadjuvant therapy have a high risk of recurrence even with neoadjuvant and adjuvant treatment with pembrolizumab.
DeMichele, Angela   +13 more
core   +1 more source

Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis

open access: yes, 2020
This study evaluates the efficacy of pembrolizumab for the treatment of advanced/metastatic melanoma. The literature search was conducted in electronic databases for studies that evaluated the efficacy and safety of pembrolizumab either alone or in ...
Huo Geng-wei   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy